Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03800134
Title	A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Acronym	AEGEAN
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	AstraZeneca
Indications	lung non-small cell carcinoma
Therapies	Cisplatin + Durvalumab + Gemcitabine Carboplatin + Paclitaxel Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Paclitaxel Cisplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Gemcitabine
Age Groups:	senior \| adult
Covered Countries	USA \| ROU \| POL \| NLD \| ITA \| HUN \| FRA \| ESP \| DEU \| CAN \| BRA \| BGR \| BEL \| AUT \| ARG